DUTTA SANDEEP,RAJEEV M. MENON,SVEN MENSING,SCOTT C. BRUN,BARRY M. BERNSTEIN,CHERI E. KLEIN,AMIT KHATRI,DANIEL E. COHEN,THOMAS J. PODSADECKI,WALID M. AWNI,EMILY O. DUMAS
申请号：
NZ60905212
公开号：
NZ609052A
申请日:
2012.10.19
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
Provided are therapeutic regimens for the treatment of hepatitis C virus (HCV). The regimens comprise the administration of at least two direct acting antiviral agents (DAAs) and ribavirin, wherein the regimens exclude interferon and last for 6, 7, 8, 9, 10, 11 or 12 weeks. In one embodiment a regimen includes the use of ribavirin, PSI-7977 (sofosbuvir), and GS-5885 (ledipasvir).
